Apatinib in Chinese patients with advanced hepatocellular carcinoma: A phase II randomized, open-label trial.-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Apatinib in Chinese patients with advanced hepatocellular carcinoma: A phase II randomized, open-label trial.

Published:2014-05-20 Issue:15_suppl Volume:32 Page:4019-4019
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Qin Shukui¹

Affiliation:

1. Nanjing Bayi Hospital, Nanjing, China

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2014.32.15_suppl.4019

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in second-line treatment research for hepatocellular carcinoma;Clinical and Translational Oncology;2024-08-20

2. Small-molecule-based targeted therapy in liver cancer;Molecular Therapy;2024-08

3. Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study;Cancer Imaging;2023-05-30

4. Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy;Livers;2023-03-13

5. Integrative analysis of multi-omics data reveals inhibition of RB1 signaling promotes apatinib resistance of hepatocellular carcinoma;International Journal of Biological Sciences;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP